

## **Aurealis Pharma to Showcase at BioTrinity 2016 - Europe's Leading Investment and Biopartnering Conference, London, April 25-27<sup>th</sup> 2016**

Basel Switzerland, Kuopio Finland – March 24<sup>th</sup> 2016.

Aurealis Pharma, a privately owned biopharmaceutical company focused on developing novel lactic acid bacteria based multitherapy biologics for patients with chronic inflammation and cancer, announced today that CEO Juha Yrjänheikki, CSO Thomas Wirth and CMO Dirk Weber will attend BioTrinity 2016 Conference in London UK on April 25-27<sup>th</sup> 2016, and will present the company and its progress at Company Showcase Presentation on Tuesday April 26<sup>th</sup> 2016 at 4:00 pm.

“We are pleased to return and showcase at the BioTrinity 2016. We have had a busy year with a lot of milestones met and anticipate that our progress will create excitement and interest within the biotech investor audience” said CEO Yrjänheikki.

Aurealis Pharma is a Basel Switzerland and Kuopio Finland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to effectively, safely and economically modulate and re-educate the distorted host immune microenvironment to proper state in chronic inflammation and cancer. Company’s technology is based on safe food-grade lactic acid bacteria delivering multiple human therapeutic proteins in target tissue to address the unmet medical need in chronic wounds and cancer.

As Europe’s leading investment and biopartnering conference, BioTrinity is the nexus of a booming life sciences innovation ecosystem and provides a unique platform for R&D, global pharma and investor companies across the life sciences industry to achieve their business objectives; to secure funding, seek acquisition and in-licensing deals and grow their network. BioTrinity is celebrating its 10 year anniversary in April 2016. To reflect the importance of this key industry event, the theme running through the programme is the ‘Vision for Life Sciences 2030’. BioTrinity 2016 will be taking place at the Novotel London West, April 25-27<sup>th</sup> 2016.

For more information:

Juha Yrjänheikki, CEO

Aurealis Pharma

Tel: +358 45 8433550

Email: [juha\(at\)aurealispharma.com](mailto:juha(at)aurealispharma.com)

[www.aurealispharma.com](http://www.aurealispharma.com)



**AUREALIS PHARMA**

Greifengasse 11

CH-4058 Basel

Switzerland

[www.aurealispharma.com](http://www.aurealispharma.com)

Microkatu 1

FI-70210 Kuopio

Finland